Ocular Immunology and Inflammation · 2013 · 40 citations · 28 references
MedicineOphthalmologyPharmacotherapyAutoimmunityInflammationRheumatologyAutoimmune Eye DiseaseAutoimmune Ocular DiseaseOcular InflammationScleral DiseaseAnti-inflammatory Ocular TherapyImmune-mediated ScleritisNoninfectious ScleritisTumor Necrosis Factor Inhibitor Therapy
PURPOSE: To evaluate the use of TNF-alpha inhibitors for non-infectious, non-necrotizing scleritis. METHODS: We conducted a retrospective chart review of patients with non-infectious, non-necrotizing scleritis treated at our institutions from 2002 to 2012. RESULTS: Seventeen patients (26 eyes) were included. Ten patients were started on infliximab and seven on adalimumab; five patients were treated with both TNF-alpha inhibitors on separate occasions. All patients had an associated autoimmune disease. Control of active inflammation for at least 2 months was achieved in 15 (88%) of 17 patients. Seven out of eight patients successfully tapered concurrent corticosteroid use. Only one patient discontinued TNF-alpha inhibitor use due to an allergic reaction. CONCLUSIONS: TNF-alpha inhibitors appear to have a role in managing non-infectious, non-necrotizing scleritis refractory to initial therapy, mainly by reducing inflammation and decreasing concurrent CS use.
28
Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease et al. · Arthritis & Rheumatism · 2009 · 603 citations
Episcleritis and scleritis: clinical features and treatment results
Douglas A. Jabs, Abdulbaki Mudun, James P. Dunn et al. · American Journal of Ophthalmology · 2000 · 389 citations
Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis
Conor C. Murphy, William Ayliffe, A. D. Booth et al. · Ophthalmology · 2004 · 188 citations
Low-dose Methotrexate Therapy for Ocular Inflammatory Disease
Sanjay S. Shah, Careen Y. Lowder, Michael Schmitt et al. · Ophthalmology · 1992 · 182 citations